At present, none has reached the stage of clinical development, but in both in vitro and in vivo experiments, it has been observed that the use of CAR-T cells targeting VEGFR1, VEGFR2, and VEGFR3 positively prolonged the survival of mice and inhibited the growth of several types of solid tumors [169,170,171,172], although none of these studies has been performed in HCC so far. This evidence concerns the gene KDR and hepatocellular carcinoma.